Studying how antibiotics work in children with bacterial meningitis and fast kidney function

Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance

This study looks at how different antibiotics work in children with bacterial meningitis and fast kidney function to see if adjusting their doses can improve treatment.

Quick facts

• Study type: Observational
• Enrollment: 300 (estimated)
• Ages: 2 Months to 18 Years
• Sex: All
• Sponsor: Shandong University (Academic / other)
• Locations: 1 site (Chongqing, Chongqing)
• Trial ID: NCT04771884 on ClinicalTrials.gov

What this trial studies

This observational study aims to investigate the population pharmacokinetics of commonly used antimicrobial agents, including meropenem, vancomycin, ceftazidime, ceftriaxone, ceftizoxime, and linezolid, in children diagnosed with bacterial meningitis who exhibit augmented renal clearance. The researchers will measure drug concentrations in both plasma and cerebrospinal fluid to understand how these medications behave in the body and to assess the feasibility of individualizing dosages based on pharmacokinetic data. The goal is to optimize treatment for this vulnerable population.

Who should consider this trial

Good fit: Ideal candidates for this study are children aged 2 months to 18 years diagnosed with bacterial meningitis and exhibiting augmented renal clearance.

Not a fit: Patients who have severe congenital malformations or are receiving other systemic experimental drug therapies may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more effective and personalized antibiotic treatments for children suffering from bacterial meningitis.

How similar studies have performed: While this approach is focused on a specific population, similar pharmacokinetic studies have shown promise in optimizing antibiotic therapy in various patient groups.

Eligibility criteria

Inclusion Criteria:

* Children have been diagnosed with bacterial meningitis with augmented renal clearance (eGFR ≥ 160 mL/(min\*1.73m2));
* Age: 2 months-18 years;
* Meropenem, vancomycin, ceftazidime, ceftriaxone, ceftizoxime and/ or linezolid used as part of regular treatment;
* Meropenem, vancomycin, ceftazidime, ceftriaxone, ceftizoxime and linezolid was administered intravenously.

Exclusion Criteria:

* Patients who die within the treatment cycle;
* Severe congenital malformation;
* Receive other systemic experimental drug therapy;
* Other factors that the researchers consider unsuitable for inclusion.

Where this trial is running

Chongqing, Chongqing

• Children's Hospital of Chongqing Medical University — Chongqing, Chongqing, China (Recruiting)

Study contacts

• Study coordinator: Wei Zhao, Phd

Conditions Bacterial Meningitis; Augmented Renal Clearance